Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Ocular Surface Disease > Innovative smartphone app shows promise in diagnosing dry eye disease
  • Ocular Surface Disease

Innovative smartphone app shows promise in diagnosing dry eye disease

Ophthalmology 360

A smartphone application (app) shows promise as a noninvasive and novel method for assisting in the diagnosis of dry eye disease (DED), according to a study that found that the app-based measurements of the Japanese version of the Ocular Surface Disease Index (J-OSDI) were equivalent to traditional paper-based measurements.

Participants then utilized the app to provide data on app-based J-OSDI and maximum blink interval (MBI). The study assessed the equivalence between app-based and traditional paper-based J-OSDI through an equivalence test. Additionally, Bland-Altman analysis was employed to evaluate the agreement between app-based and manually measured MBIs. The screening performance of the app was further analyzed using Receiver Operating Characteristic (ROC) analysis.

Results from the study demonstrated that the app-based and paper-based J-OSDIs were found to be equivalent among the 34 participants, with a mean difference of 1.8 (95% CI, −1.4 to 5.0). Bland-Altman analysis for agreement on MBI between the app and manual measurements revealed biases of −0.08 (n = 83, limits of agreement: −0.76 to 0.60). The app exhibited a positive predictive value of 91.3%, and the area under the ROC curve was 0.910 among the 84 participants.

These findings suggest that the smartphone app presents a novel and noninvasive method for aiding in the diagnosis of dry eye disease. The positive results from the equivalence and agreement tests, along with the high predictive value and ROC curve performance, indicate the app’s potential as an effective tool in the early detection and monitoring of DED

Reference
Okumura Y, et al. A Feasibility of a Smartphone Application to Assist Diagnosis of Dry Eye. Poster Presented at: AAO 2023.

Share

Related Content

  • Ocular Surface Disease

Scleral lenses improve vision and symptoms across ocular surface diseases

  • Dry Eye

Spotlight on LACRIFILL®

  • Glaucoma

Review finds low adverse event rates for glaucoma stents

  • Retina

Switching to aflibercept 8 mg extends treatment intervals in suboptimal nARMD responders

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon